Information Provided By: 
Fly News Breaks for July 15, 2019
PSNL
Jul 15, 2019 | 07:14 EDT
Oppenheimer analyst Kevin DeGeeter started coverage of Personalis with an Outperform rating and $29 price target. The analyst views it as well positioned to benefit from secular growth trends in oncology drug development and expects the company to solidify its position as a preferred provider of genetic testing services to pharmaceutical clients, based on channel checks suggesting a high level of customer support, maturing landscape requiring more complex diagnostic testing, and upside from clinical trials of personalized neoantigen products.
News For PSNL From the Last 2 Days
There are no results for your query PSNL
